Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors

The PI3K-AKT kinase signaling pathway is frequently deregulated in human cancers, particularly breast cancer, where amplification and somatic mutations of PIK3CA occur with high frequency in patients. Numerous small-molecule inhibitors targeting both PI3K and AKT are under clinical evaluation, but dose-limiting toxicities and the emergence of resistance limit therapeutic efficacy. Various resistance mechanisms to PI3K inhibitors have been identified, including de novo mutations, feedback activation of AKT, or cross-talk pathways. We found a previously unknown resistance mechanism to PI3K pathway inhibition that results in AKT rebound activation. In a subset of triple-negative breast cancer cell lines, treatment with a PI3K inhibitor or depletion of PIK3CA expression ultimately promoted AKT reactivation in a manner dependent on the E3 ubiquitin ligase Skp2, the kinases IGF-1R (insulin-like growth factor 1 receptor) and PDK-1 (phosphoinositide-dependent kinase-1), and the cell growth and metabolism-regulating complex mTORC2 (mechanistic target of rapamycin complex 2), but was independent of PI3K activity or PIP3 production. Resistance to PI3K inhibitors correlated with the increased abundance of Skp2, ubiquitylation of AKT, cell proliferation in culture, and xenograft tumor growth in mice. These findings reveal a ubiquitin signaling feedback mechanism by which PI3K inhibitor resistance may emerge in aggressive breast cancer cells.
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Tags: STKE Research Articles Source Type: news

Related Links:

Many U.S. breast imaging facilities don't have structures in place to establish...Read more on AuntMinnie.comRelated Reading: What do women want in a breast imaging center? 6 tips for top-notch breast cancer risk assessment Tweets reveal women's perspectives on mammography NCBC: Breast centers must reach out to survive Will Etheridge's breast cancer up screening in gay community?
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Are oncologists recommending less chemotherapy for early breast cancer?Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
A new  studyhas found that false positive breast cancer biopsies are costing healthcare facilities over $2.1 billion annually. This high false positive rate and the consequential expenses highlight the need for improved breast cancer diagnostic protocols and technology.Researchers from IBM Watson Health and Seno Medical looked at health care claims filed between 2011 and 2015 from 875,000 women to understand the rate of follow-up procedures after mammography and breast exams. They found that between 2012 and 2015, 8,732,909 patients received diagnostic mammograms, 6,987,399 underwent breast ultrasounds, and 1,585,856 ...
Source: radRounds - Category: Radiology Authors: Source Type: blogs
Researchers from the Institute of Cancer Research, London, found that carrying too little weight between the ages of 18 and 24 is particularly risky. Women should not deliberately gain weight.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Former Puma Biotechnology executive, Robert Gadimian, was sentenced to prison for illegally trading on inside information about a breast cancer drug.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
A breast surgeon in Gainesville, VA, has launched an online resource called...Read more on AuntMinnie.comRelated Reading: Should Pink October really be Pink February? Hospital websites must improve mammography patient info After breast cancer diagnosis, women turn to texting Siemens launches breast cancer education video VuCOMP launches breast education programs
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Condition:   Triple Negative Breast Cancer Intervention:   Biological: PVSRIPO Sponsors:   Istari Oncology, Inc.;   Duke University;   United States Department of Defense Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Survivorship Interventions:   Behavioral: Lighter intensity physical activity intervention;   Behavioral: Higher intensity physical activity intervention Sponsors:   AHS Cancer Control Alberta;   Carole May Yates Memorial Endowment for Cancer Research;   O'Brien Institute for Public Health Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Environmental Health | Insulin | Science | Toxicology